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Recently, accumulating evidences have revealed that neuroinflammation seems to be the 
cornerstone of many neurological diseases including stroke, multiple sclerosis, Alzheimer’s 
disease or Parkinson’s disease. Neuroinflammation causes neuronal damages by activation of 
plenty of cells and molecular mediators in diseases involving inflammatory process. We focus 
on non-invasive molecular imaging of radioligands that target inflammatory cells and 
molecules involved in neuroinflammation. Indeed, PET is one of the most promising imaging 
techniques to visualize and quantify neuroinflammation in vivo. We summarize here the 
potential neuroinflammation imaging targets and corresponding PET radioligands. 
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Résumé + mots clefs 
 
Des données scientifiques récentes et de plus en plus nombreuses ont mis en évidence le rôle 
central joué par le processus de neuroinflammation dans la physiopathologie de nombreuses 
maladies neurologiques, telles que l'accident vasculaire cérébral, la sclérose en plaques, la 
maladie d'Alzheimer ou encore la maladie de Parkinson. Dans ces maladies impliquant le 
processus inflammatoire, la neuroinflammation cause en effet des dommages neuronaux par 
activation de nombreuses cellules et médiateurs moléculaires. 
L’imagerie de Tomographie par Emission de Positons (TEP) apparaît comme une approche 
prometteuse pour visualiser et quantifier in vivo la neuroinflammation de façon non-invasive, 
grâce en particulier au développement de radioligands ciblant spécifiquement diverses 
molécules impliquées dans cette réaction inflammatoire cérébrale. Dans cette revue sont 
présentés les cibles moléculaires potentielles pour l’imagerie TEP de la neuroinflammation 
ainsi que les médicaments radiopharmaceutiques correspondants. 
 
Mots-clefs : Médicament Radiopharmaceutique – Tomographie par Emission de Positons – 
Neuroinflammation – Imagerie moléculaire- Microglie.  
1 Introduction 
1.1  Neuroinflammation pathophysiology 
Inflammation is a complex physiological response to different types of tissue injuries. The 
inflammatory reaction is an effective protective mechanism via the activation of a cascade of 
coordinated chemical and cellular reactions. Typically, this inflammatory cascade involves a 
local production of cytokines, which lead to a cell recruitment and differentiation. 
The central nervous system (CNS) is characterized by a limited regenerative capacity and 
immune specificities such as the presence of a blood-brain barrier (BBB). Neuroinflammation 
is mostly mediated by microglia, which are mesoderm-derived immunocompetent cells of the 
CNS constituting the first line of the defence immune system of the brain when the BBB is 
maintained. Microglial cells, that constitute 10% of the entire cell population of the brain (1) 
are thus the main actors of the innate (nonspecific) immune response of the CNS. The purpose 
of neuroinflammation is to eliminate the initial cause of cell injury and to initiate tissue repair. 
However, neuroinflammation may also contribute to the disease process itself. Indeed 
microglia change from a resting to an activated state in response to CNS insults that stimulate 
them (2). Therefore, different degrees of microglia activation are seen in neurodegenerative 
disorders as Alzheimer’s disease (AD), Multiple Sclerosis (MS) or Parkinson’s disease (PD). 
In addition to their phagocyte role, activated microglia in chronic neuroinflammation causes 
long-term cerebral damage by inducing autoimmune reaction. 
 
1.2 Neuroinflammation as a polyvalent biomarker 
All neurological disorders whether degenerative (AD) or acute (stroke) induce destruction or 
neuronal death. Nevertheless affected neuronal population disease progression and 
pathophysiological process are strongly different. Despite these neuronal alterations 
variabilities, they have in common the neuroinflammation process localized in affected 
cerebral areas. 
 
This has led to increasing interest in visualizing neuroinflammation in a noninvasive manner 
that would lead to better understanding of neuroinflammation and its role in brain diseases. 
The in vivo detection of activated microglia may be used as a surrogate marker of neuronal 
damage and CNS disease activity. Molecular imaging can visualize, characterize, and 
measure the biological processes at the molecular and cellular levels in humans (3). Among 
the many molecular imaging techniques, Positron Emission Tomography (PET) features high 
sensitivity and specificity. Therefore, PET has become one the most frequently used 
molecular imaging method in clinical research setting.  
As several neurodegenerative disorders are accompanied by increase in activated microglia, 
PET imaging of microglia with specific ligand may be able to assist the early detection of 
neuroinflammation. The large number of candidate Translocator Protein (TSPO) ligands that 
have been radiolabelled recently witnesses a strongly growing interest for this target. 
Consequently, new imaging targets and tracers for more specific neuroinflammation detection 
and in vivo characterisation are under intensive investigation.  
 
In Figure 1, we summarized radiopharmaceuticals developed for PET imaging of 
neuroinflammation, targeting different biomarkers. 
 
2 Potential targets for neuroinflammation molecular imaging 
2.1 Current state of molecular targets for PET imaging 
2.1.1 Cerebral blood flow and carbohydrate metabolism variation 
Neuroinflammation is associated with several physiological parameters alteration such as 
cerebral blood flow variation or carbohydrate metabolism modification. Molecular imaging 
could use these physiological changes to visualize neuroinflammation in non-invasive 
procedure, in order to better understand brain diseases physiopathology, to improve the 
diagnosis and to assess novel therapies in vivo. 18F-FDG (2-deoxy-2-18F-fluoro-D-glucose) is 
the most extensively used PET tracer. It has been applied successfully in tumor detection, 
progression, and therapy evaluation but a high rate of glucose metabolism is also found in 
active white blood cells so 18F-FDG PET has been performed in several studies of infection 
and inflammation (4).  
 
Although cerebral blood flow modification and carbohydrate metabolism have been 
successful exploited to detect cerebral inflammation by PET or SPECT, these parameters are 
not enough specific of the inflammatory process and could be induced by other physiological 
causes. 
   
2.1.2 Microglia and TSPO 
2.1.2.1 TSPO structure and functions 
The 18-kDa translocator protein (TSPO) is a hetero-oligomeric complex located on the outer 
membrane of mitochondria (5)(6). It has been first described as peripheral benzodiazepine 
receptor (PBR), a secondary binding site for diazepam which is distinct in its structure and 
whole body distribution from the central benzodiazepine receptor (CBR). Whereas CBR is 
mostly expressed in the brain, PBR (or TSPO) has an ubiquitous distribution in most 
peripheral organs including the kidney, the heart and particularly in the steroid producing 
tissues. TSPO remains minimally expressed in the normal healthy brain, and its basal 
expression rises in several acute and degenerative disorders including stroke, Alzheimer’s 
disease, Parkinson’s disease, multiple sclerosis and amytrophic lateral sclerosis (7). The 
TSPO is known to be involved in modulating immune response, porphyrin transport and heme 
synthesis, regulation of cell proliferation, steroid biosynthesis and programmed cell death (8). 
Active brain disease is responsible for a change from rest to active state of microglia and this 
state change is associated with de novo expression of the TSPO. It is generally accepted that 
an increase in TSPO density is a reliable biomarker of microglial activation and 
neuroinflammation. Therefore the use of high affinity TSPO ligands for PET may greatly help 
for in vivo study of both acute and chronic neuroinflammatory conditions. 
 
2.1.2.2 Radioligands for the TSPO 
In addition to many endogenous compounds, TSPO binds a range of synthetic ligands. Thus, 
several classes of TSPO radioligands have already been synthesized, with, for most of them, 
the availability of compounds radiolabelled with carbon-11 or fluorine-18. We proposed here 
a classification of these compounds according to their chemical structure.  
 
Over the last years, several structure activity relationship studies have laid out that four main 
domains are necessary for a ligand to interact with the TSPO (9)(10)(11). These 




Historically, the benzodiazepine 11C-Ro5-4864 (Figure 2) was the first ligand able to 
discriminate peripheral from CBR. Initial PET imaging with 11C-Ro5-4864 in patients with 
brain tumours did not show great promise because of large amounts of nonspecific binding 
and low in vitro affinity in human brain tissue (13). This nonspecific binding is related to 
lipophilic and electrostatic (π- π) interactions between the radioligand and the brain tissue 
especially in the white matter. This limitation is not specific to TSPO PET imaging but is also 
met for mostly of PET brain radiopharmaceuticals. 
 
2.1.2.4 Isoquinoline carboxamide 
PK 11195 (Figure 3), a lipid soluble 3- Isoquinoline carboxamide was the first non-
benzodiazepine type compound identified to bind to TSPO with high affinity (human Kd= 
2nM)(14). In vitro and in vivo studies in both rats and mice demonstrated the superior binding 
affinity of PK 11195 compared to Ro5-4864. PK 11195 has been used in the majority of 
TSPO PET studies so far (15) and, hence has been tagged the gold standard of TSPO ligands. 
 
The binding sites of the benzodiazepine Ro5-4864 and the Isoquinoline carboxamide 
derivative PK11195 on TSPO have distinct but overlapping sequences that involve amino 
acid residues on the first cytoplasmic loop and the C-terminal (16).  
 
Despite 11C-PK11195 has been widely used in both animals and human research, it showed 
several drawbacks : it displayed a poor signal-to-noise ratio, a low BBB permeability and a 
high level of nonspecific binding (15). For these reasons the sensitivity of PK 11195 in 
assessing and studying the TSPO is limited (17). In addition, 11C has a very short radioactive 
half-time of only 20 minutes which also negatively affects widespread clinical use. 
 
2.1.2.5 Phenoxyarylacetamides 
An important group of new TSPO radiotracers are the derivatives of Phenoxyarylacetamides. 
N-(4-chloro-2-phenoxyphenyl)-N-(2-isopropoxybenzyl)acetamide (DAA1097) and N-(2,5-
dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl)acetamide (DAA 1106) (Figure 4), are 
specific ligands for TSPO (18) with a chemical structure based on the opening of the 
diazepine ring of Ro5-4864. They display potent anxiolytic effects in laboratory animals (19). 
Both ligands have been shown to inhibit 3H-PK 11195 binding to mitochondrial preparations 
of rats whole brain with IC50 values of 0.92 and 0.28 nM respectively (PK 11195, 
IC50=1.12nM)(19). DAA 1106 is not species dependent as it binds with high affinity to both 
monkey and rat brains having Ki values of 0.0188 nM and 0.043 nM respectively (20). 
 
The currently leading TSPO radiotracers derivatives from DAA 1106 include the 11C-PBR28 
(21), 11C-PBR06 (22), 18F-FEPPA (23). Despite the considerable improvements exhibited by 
these TSPO radiotracers, most developed are less than ideal because of a significant 
component of nonspecific binding. 
 
2.1.2.6 Imidazopyridines 
The imidazopyridines were extensively evaluated in rodents and many of these compounds 
displayed improved biological characteristics, such as a higher target-to-background signal, 
faster clearance from nonspecific tissue and improved metabolic stability relative to 11C-PK 
11195 in in vivo animal’s studies. Five of these radiotracers (123I-CLINDE, 123I/11C-CLINME, 
18F-PBR111, 18F-PBR102) (Figure 5) have further been evaluated in several rodent animal 
models of disease confirming that these radiotracers can image and measure activated 
microglia in the CNS (24)(25)(26). 
 
2.1.2.7 Pyrazolopyrimidines  
The series of pyrazolo [1,5-a] pyrimidine was published in 2001 (27), with two promising 
candidates for molecular imaging of neuroinflammation: The 11C-DPA-713 and 18F-DPA-
714. 
 The DPA-713, or N, N-diethyl-2- [2- (4-methoxyphenyl) -5,7-dimethyl-pyrazolo [1,5-a] 
pyrimidin-3-yl] -acetamide (Figure 6 (1 )), has a lower lipophilicity than PK11195, and good 
in vitro affinity for TSPO (Ki = 4.7 nM in rat kidney tissue). In baboon, a pre-injection of an 
excess of cold PK11195 blocks about 70% of brain binding of 11C-DPA-713, indicating good 
radioligand binding specificity to TSPO. The relatively slow kinetics of the 11C-DPA-713, 
with a peak maximum at 20 minutes post-injection allows accurate quantification of the 
measured signal. The 11C-DPA-713 was evaluated in a model of inflammation in rats 
(intrastriatal injection of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)), 
where it showed its ability to visualize activated microglia with a specific signal TSPO and 
higher Binding Potential than 11C-PK11195, due to lower cerebral non-specific binding (28). 
The 11C-DPA-713 was also evaluated in healthy humans, and has shown a good in vivo 
kinetics and stability properties for human PET exploration of neuroinflammation (29). 
 
The DPA-714, or N,N-diéthyl-2-(2-[4-(2-fluoroéthoxy)-phényl]-5,7-diméthyl-pyrazolo[1,5-
a]pyrimidin-3-yl)-acétamide (Figure 6 (2)), exhibits a correct in vitro affinity for TSPO, even 
if slightly smaller than that of the DPA-713 (Ki = 7.0 nM rat kidney tissue, as measured by 
displacement of [3H] -PK11195 ), and excellent selectivity for TSPO respectively to the CBR. 
The 18F-DPA-714 enabled to visualize the activated microglia in rats in a model of excitotoxic 
lesion (30) and in a model of cerebral ischemia (31)(30). In monkeys, the 18F-DPA-714 passes 
the BBB and accumulates in the brain with good specificity for TSPO, characterized by 
pretreatment with PK11195. 
  
The 18F-DPA-714 has also been successfully evaluated in healthy humans, and in several 
brain diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis, and stroke, showing 
its ability to visualize and quantify neuroinflammation in a clinical pathological setting 
(32)(33)(34)(35)(36). 
 
2.1.2.8 TSPO imaging limitations 
TSPO PET radiopharmaceuticals have been intensively used to explore neuroinflammation in 
the framework of clinical studies during these ten last years (see Part 3 below for a summary),  
but these studies also evidence several limitations of this approach, specifically associated 
with three properties of TSPO as a molecular biomarker of neuroinflammation. 
 
- The mathematical model usually applied to quantify the TSPO radioligands binding 
requires a dynamic PET acquisition and the definition of a region that does not contain 
specific ligand binding, from which to draw the “normal” kinetic behaviour that does 
not contain specific ligand binding. However, microglia are distributed throughout the 
entire brain, and in a disease such as neurodegenerative pathology no clear reference 
region may a-priori exist. Cluster analysis should then be performed on the dynamic 
PET scan of each subject to determine a suitable reference region.  
 
- A genetic polymorphism in the TSPO gene (rs6971) has been identified to cause the 
substitution of an amino-acid in the TSPO structure (A 147T). This polymorphism 
affects the binding affinity properties of most of PET TSPO radiopharmaceuticals for 
their target, with a huge heterogeneity in PET images and their associated quantitative 
data (37). Three classes of individuals have been described in relation with this 
polymorphism: high-affinity binders (HABs, ≈ 66% of the Caucasian population); 
mixed-affinity binders (MABs, ≈ 29%); and low-affinity binders (LABs, ≈ 5%). In in 
vivo PET studies, the binding of the radioligand depends on the class to which the 
subject belongs, but also on the radiopharmaceutical used (38). Then, genetic status 
regarding TSPO polymorphism is now required in clinical setting, but cross-studies 
analysis remains difficult when various radiopharmaceuticals are used in these studies, 
even if mathematical models (39) as well as new radioligands with low sensitivity to 
this polymorphism have (40) recently been proposed.   
 
- Recently, there is emerging hypothesis accounting for that microglia is tuned for 
different types of host defense and protection, with a continuum of phenotypes from a 
proinflammatory and cytotoxic mediator state to a protective state that can dampen 
inflammation and promote tissue regeneration. Therefore, based largely on these 
observations, the microglial cells seem to have neuroprotective and neurotoxic roles, 
slowing and accelerating disease progression, respectively. Moreover, the same 
microglia cell may change alternatively from these two extreme states during disease 
progression. Yet, PET TSPO radiopharmaceuticals are not able to differentiate theses 
pro- or anti-inflammatory phenotypic and functional states of microglia, since TSPO is 
expressed similarly in both activated states (41). Therefore, such investigations would 
require the identification of new molecular targets and development of new 
radiopharmaceuticals able to differentiate the damaging from the neuroprotective 
microglia phenotypes, to increase the understanding of disease pathogenesis, as well 
as to help to develop novel therapeutic approaches. 
 
2.2 Further neuroinflammation PET imaging targets 
2.2.1 Cox2  
The cyclooxygenase is an enzyme that is involved in the initial stages of the synthesis of 
prostaglandines. The subtype 2 (COX-2) is an inducible isoform that is activated during the 
inflammatory reaction. This enzyme is expressed in very low concentration in the healthy 
brain, but its expression increases in a very important way further to an inflammatory 
stimulus, in particular in the cells of the activated microglia and in the astrocytes (42). The in 
vivo imaging of the COX-2 could supply valuable information about its exact role when it is 
overexpressed during an inflammatory process (43). The celecoxib is a selective inhibitor of 
the COX-2 and had been radiolabelled with the metastable technetium-99 (44). This 
radioligand showed an accumulation in cells expressing strongly the COX-2, but the specific 
binding has never been shown in vitro or in vivo. 
 
More recently, several other selective inhibitors of the COX-2 as the 11C-etoricoxib (45) and 
the 11C-rofecoxib were described. Nevertheless, the evaluation of these molecules for the PET 
imaging in animal models of neuroinflammation has been disappointing (46).  
 
2.2.2 Metalloproteinases and proteolytic activity  
Proteases such as matrix metalloproteinases (MMPs) are crucial mediators of tissue damage 
secreted by microglia, astrocytes and monocytes. Altogether MMPs can degrade all the 
components of the extracellular matrix, and must be thus regulated finely. They are generally 
little expressed in healthy tissues, but their expression increases during the processes of 
tissular physiological or pathological remodelling under the influence of factors to modulate 
the expression of their genes (IL-1, TNFα, prostaglandins, cellular lesion). In the CNS, MMPs 
are associated with excitotoxicity, neuronal damage (47), and opening of the BBB (48). 
Locally increased levels of activated MMPs modulate and contribute to the progression of 
various diseases, such as stroke. Therefore, activated MMPs are suitable biological targets for 
the specific and non-invasive visualization of these pathologies in vivo. Recently, 
radiolabelled C-5-disubstituted pyrimidine-2,4,6-triones have been suggested by the 
University Hospital of Münster, Germany, as a class of potent MMPs targeted radiotracers 
that can non-invasively visualize activated MMPs by means of PET(49). This novel MMPs 
radiotracer is characterized by an increased hydrophilicity compared with the lead structures 
and excellent MMP inhibition potencies for several MMPs(MMP-2, MMP-8, MMP-9, and 
MMP-13) (IC50 = 0.006−107 nM)(49).  
 
2.2.3 Cannabinoid receptor 2 (CB2)  
While the cannabinoid receptor 1 is constitutively expressed in a variety of cell types, CB2 is 
thought to be expressed on microglia/macrophages and is upregulated with activation of these 
cells (50). The cannabinoid type 2 (CB2) receptor plays an important role in 
neuroinflammatory and neurodegenerative diseases such as multiple sclerosis, amyotrophic 
lateral sclerosis, and Alzheimer’s disease and is therefore a very promising target for 
therapeutic approaches as well as for imaging. The 11C-A836339 has been evaluated and 
reported to be a selective CB2 agonist with high binding affinity. It shows specific cerebral 
uptake in the brain areas with Aβ amyloid plaque deposition in a mouse model of Alzheimer's 
disease (APPswe/PS1dE9 mice). These data establish a proof of principle that CB2 receptors 
binding in the neuroinflammation and related disorders can be measured in vivo in 
neuroinflammation and related disorders (51). Turkman and al(52), reported synthesis and 
results of in vitro receptor binding of two fluorinated 2-oxoquinoline derivatives, the 18F-13 
and 18F-14 (Figure 7) as CB2 receptor ligands. In vitro CB2 receptor binding assay was 
performed using U87 cells transduced with CB2- and CB1-receptor and ex vivo 
autoradiography was performed with 18F-14 on spleen and on CB2- and CB1-expressing and 
wild-type U87 subcutaneous tumours grown in mice. Ex vivo autoradiography showed 
accumulation of 18F-14 in the CB2-expressing tumour. Compound 18F-14 appears to be a 
potential PET imaging agent for the assessment of CB2 receptor expression; however, poor 
solubility restrains its use in vivo.  
 
More recently, Mu and al have identiﬁed the KD2 compound, (Figure 8) which belongs to a 
new type of structure cluster, the 4-oxoquinoline derivative compared to the published CB2 
ligands such as 2-oxo-quinoline derivatives and N-arylamideoxadiazole derivatives (53). In 
vitro autoradiography with slices from rat and mouse spleen, which contain high levels of 
CB2, as well as in vivo PET of the rat spleen, demonstrated high speciﬁc and selective 





Nitric oxide (NO), plays a key role in various physiological processes such as peripheral 
blood pressure regulation and also acts as a messenger in the brain. Thus, several studies have 
shown that overproduction of NO is associated with central pathological states (54). 
Overproduction of NO by inducible enzyme nitric oxide synthase (iNOS) has been implicated 
in the functional tissue destruction of chronic inflammation. In an effort to develop a tracer 
for probing inducible nitric oxide synthase (iNOS) levels in vivo utilizing PET, two positron-
emitting iNOS selective inhibitors S-[11C]methylisothiourea and S-(2-[18F]fluoroethyl)- 
isothiourea have been synthesized and evaluated by Zhang and al (55). An in vitro model, 
J774 macrophage cell line, was used to assess the uptake of radiolabeled iNOS inhibitor in 
response to iNOS induction at the cellular level. Increased cell uptake of these two labelled 
compounds to iNOS, as well as blocking under controlled in vitro conditions, were observed. 
These preliminary results are encouraging in view of further use for in vivo detection of 
iNOS.  
 In 2009, the 18F-6-(2-fluoropropyl)-4-methylpyridin-2-amine has been assessed in vivo in a 
mouse model of lipopolysaccharide (LPS)-induced iNOS activation (56). In vivo 
biodistribution studies indicate higher tracer uptake in the lungs of the LPS-treated mice when 
compared to control mice. Data suggest that 18F-6-(2-fluoropropyl)-4-methylpyridin-2-amine 
shows favourable features as a PET tracer to image iNOS activation with PET.  
 
2.2.5 β-glucuronidase 
It has been shown an increased in release of β-glucuronidase by activated microglia into the 
extracellular space at the site of neuroinflammation (57)(58). Therefore, β-glucuronidase 
might be a biomarker for neuroinflammation. Antunes et al (59), have designed a PET tracer 
for β-glucuronidase imaging from a glucuronide-prodrug-based structure coupled to a 
radioactive 18F-fluoroethylaminegroup. They investigated whether β-glucuronidase is released 
during neuroinflammation in a rat model of herpes encephalitis (brain lysosomal hydrolase 
activities increase after infection with viruses) using this specific PET tracer, the 18F-
FEAnGA (Figure 9). A significant enhancement of the distribution volume of the tracer in 
the brains of HSV-1-infected rats was observed compared with the brains of uninfected rats. 
However 18F-FEAnGA uptake in the brain was low in both control and in infected animals. 
 
2.2.6 P2X7 
The P2X7 ion channel receptor is one of the numerous P2X purinergic receptors which are 
found in the immune, peripheral and central nervous systems and is implicated in ATP-
mediated cell death (60). P2X7 is involved in the release of pro-inflammatory cytokines (61) 
and thus plays a role in peripheral inflammatory diseases. However several researchs have 
evidence the role of P2X7 on neuroinflammatory conditions such as Alzheimer’s disease, 
epilepsy and other CNS disorders(62)(63). 
 
In activated microglia, the purinergic P2X7 receptor is upregulated.  A-740003, a highly affine 
and selective P2X7 receptor antagonist, was a promising candidate for the development of a 
radiotracer for imaging of neuroinflammation by PET. For this purpose, 11C-A-740003 
(Figure 10) was synthesised and evaluated in vivo showing little uptake in rat healthy brain 
(64). 
 
Then, GlaxoSmithKline has developed GSK1482160 (Figure 10), a potent P2X7 antagonist 
with good  biological activity (IC50=3nM for human P2X7)(65). This compound readily 
crosses the blood-brain-barrier and has been evaluated as a therapeutic agent in phase 1 
human study (65) making it radiolabelled entity an attractive PET diagnostic agent candidate. 
The recent growth of the P2X7 antagonists development has led to the discovery of a novel 
series of compounds (methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl)methanone) (Figure 11) with good drug-like properties with high P2X7 receptor 
occupancy in rat following oral administration (66). The compound displayed on figure 10 
appears to be viable candidate as a tracer for PET imaging. Additional efforts on related 
compounds should be confirm this hypothesis. 
 
2.2.7 P2Y12 
The P2Y12 receptor is an ADP-responsive G protein–coupled receptor expressed on the 
surface of platelets and is the pharmacologic target of several antithrombotic agents (67). In 
the CNS, P2Y12 expression is limited to the ramified processes of microglia. In humans, the 
role of P2Y12 expression in microglia is unknown. Moore et al. investigated the significance 
of P2Y12 expression in the context of human brain injury and repair (68). They show that 
P2Y12 increases following interleukin (IL)-4 and IL-13 activation, and mediates cell 
migration and inflammatory responses. Identifying P2Y12 as a molecule associated with the 
M2 tissue regenerative phenotype may help to discover novel therapeutic targets and 
mechanisms that promote CNS repair.  
 
3 Clinical Challenge and perspective 
Detection of neuroinflammation in vivo throughout the course of neurodegenerative diseases 
is of great clinical interest. Studies have shown that microglia activation, as an indicator of 
neuroinflammation, may present at early stages of several dementias diseases, like 
Alzheimer’s disease (AD) or frontotemporal dementia (FTD), but its role in their 
pathogenesis is largely unknown. PET ligands for neuroinflammation may act as surrogate 
markers of disease progression, as well as for the measuring of target engagement in the 
context of clinical trials (69)(70).  
 
AD, the most common cause of dementia in elderly subjects has been reconceptualised as a 
dynamic pathophysiological process, where the accumulation of amyloid-beta (Aβ) is thought 
to trigger a cascade of neurodegenerative events resulting in cognitive impairment and, 
eventually, dementia. In addition to Aβ pathology, various lines of research have implicated 
neuroinflammation as an important participant in AD pathophysiology(69).  
 
In other neurodegenerative diseases, like Parkinson's disease and Parkinson's disease 
dementia, microglial activation suggests a chronic inflammatory process, although there is 
also evidence of its association with cognitive ability and neuronal function (71). 
 
Evidence from both human post mortem, and in vivo animal model studies implicate the 
neuroimmune system and activated microglia in the pathology of amyotrophic lateral 
sclerosis (ALS). There is growing evidence of activated microglia and inflammatory 
processes in the cerebral cortex in ALS. This finding might improve our understanding of the 
pathophysiology of ALS and might be a surrogate marker of efficacy of treatment on 
microglial activation (72).  
 
In multiple sclerosis (MS), recent developments in PET imaging offer the potential to assess 
brain complementary informations that can not be achieved by MRI modality. Thus PET in 
MS could be used for the investigation of underlying pathophysiology of neuroinflammation, 
neuronal dysfunction, and demyelination, and remyelination. Quantitative measures of 
molecular targets with PET could also have future uses in clinical trials of drug development 
(73). 
 
Although different mechanisms are involved in the pathogenesis of stroke, increasing 
evidence suggests that inflammation, mainly involving the microglial and the immune system 
cells, account for its pathogenic progression. Cerebral ischemia rapidly evolves to necrosis 
and a peri-necrosis area of ischemic penumbra in which the brain tissue is still viable for a 
few hours. This cerebral tissue can be preserved if treatment is initiated quickly to restore the 
cerebral blood flow. Thus, this area of “darkness” is the prime target for potential 
neuroprotective drugs (33). 
 
A plethora of evidence points toward an undeniable role of brain inflammation in 
epileptogenesis. However, the exact role of this process remains unfortunately not clear. Non-
invasive imaging of brain inflammation can promote our fundamental knowledge, which may 
lead to better insights into the role of brain inflammation in disease ontogenesis and to 
investigate if anti-inflammatory therapy may play a role in treating drug-resistant epilepsy 
(74).  
 
Recently studies have suggested that neuroinflammation might be an early pathology of 
schizophrenia that later leads to neurodegeneration, yet the exact role in the etiology, as well 
as the source of neuroinflammation, are still not known. The hypothesis of neuroinflammation 
involvement in schizophrenia is quickly gaining popularity, and thus it is imperative that we 
have reliable and reproducible tools and measures that are both sensitive, and, most 
importantly, specific to neuroinflammation. Microglial activity is elevated in patients with 
schizophrenia and in persons with subclinical symptoms who are at ultra-high risk of 
psychosis and is related to at-risk symptom severity. These findings suggest that 
neuroinflammation is linked to the risk of psychosis and related disorders, as well as the 
expression of subclinical symptoms(75)(76)(77).  
 
The in vivo quantification of activated microglia with PET imaging may be an interesting tool 
for attaining a better understanding of the physiopathology of different diseases. For example, 
in AD, to evaluate the chronological relationship between the hallmarks of the disease 
(especially amyloid load) and microglia activation. In fact, the role of neuroinflammation and 
its relationship to Aß remain controversial.  
 
As exposed previously in this review, microglia are distributed throughout the entire brain, 
and in a disease such as neurodegenerative pathology no clear reference region may exist. 
Cluster analysis was therefore performed on the dynamic PET scan of each subject to 
optimize the selection of a suitable reference region. But these methods are difficult to apply 
in clinical setting and still require improvements (32). Recently, Lyoo et al, have measured 
TSPO density in AD patients and control subjects, using a simple ratio method SUVR which 
can substitute for, and may even be more sensitive than, absolute quantitation. The SUVR 
method is expected to improve subject tolerability by allowing shorter scanning time and not 
requiring arterial catheterization. In addition, this ratio method allows smaller sample sizes for 
comparable statistical significance because of the relatively low variability of the ratio values 
(78).  
 
In acute and focal diseases, like stroke, a ratio method using the contralateral to the brain 
injury tissue as reference could be used to evaluate the TSPO density. In this kind of 
situations, a 10 to 20 min of PET emission acquisition performed between 40 and 80 min pi 
was able to differentiate acute tissue injury from normal brain tissue (33).  
 
4 Conclusion 
Neuroinflammation is a physiological response to various stimuli and is increasingly 
recognized as a key factor in the pathogenesis of neurodegenerative conditions. 
Neuroinflammation is correlated with tissue damages such as neuronal loss or demyelination. 
Therefore, PET radiopharmaceuticals targeting key players in the inflammation process stand 
for an attractive and powerful imaging biomarkers. Over the last years, many 
neuroinflammatory targets have been identified and corresponding molecular imaging tracers 
developed. Among these targets, TSPO remains currently the “gold-standard” PET target for 
neuroinflammation PET exploration. 
However, recent findings evidenced a TSPO polymorphism resulting in differences in binding 
affinity of PET radioligands for TSPO. Furthermore, neuroinflammation imaging challenge 
needs henceforth to be based on various microglial phenotypes identification, in order to 
evidence its protective or damaging role. To date, the main challenge does not seem to 
develop a new “best” TSPO PET radiopharmaceutical, but rather to propose a new molecular 
target, which would own the following “ideal” criteria: 
- Identification of a brain reference region devoid of the molecular target expression, in 
absence of any inflammatory process. 
- Lack of interindividual variability and/or affinity expression, linked to a potential 
genetic polymorphism, affecting PET radiopharmaceutical’s binding. 
- Difference of its expression between the damaging and the neuroprotective continuum 
phenotypic expression of microglia cells. 
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Figures and Legends 
Figure 1 
Neuroinflammation targets for PET imaging in brain cellular environment (adapted from Wu, 
Theranostics. 2013;3(7):448-66) 
Cibles de la neuroinflammation pour l’imagerie TEP dans l’environnement cellulaire cérébral 




 Figure 2 
Chemical structure of the : (A) Diazepam ; (B) Ro5-4864 
Structure chimique du : (A) Diazepam ; (B) Ro5-4864 
 
Figure 3 
Chemical structure of the PK 11195 




Chemical structure of the DAA1106 
Structure chimique du DAA1106 
 Figure 5 
Chemical structure of the CLINDE 




Chemical structure of the radiolabeled compounds of the series-pyrazolo [1,5-a] pyrimidine  




 Figure 7 
Chemical structure of the 18F-13 and 18F-14 




Chemical structure of the 11C-KD2  





Chemical structure of the 18F-FEAnGA 
Structure chimique du 18F-FEAnGA 
 Figure 10 
Chemical structure of the : (A)11C-A-740003 ; (B)11C-GSK1482160 ; (C)11C-GSK1482160 
isomer 





Chemical structure of the Methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-
7(8H)-yl)methanone derivative 
Structure chimique du dérivé methyl substitué 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-
7(8H)-yl)methanone  
 
